New Therapeutic Options in Therapy of Glioblastoma Multiforme

Česká verzia

Authors: R. Lakomý ^1,2; P. Burkoň ^1,3; D. Burkoňová ^1,3; R. Jančálek ^1,4
Authors place of work: Lékařská fakulta, Masarykova univerzita Brno ¹; Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno ²; Klinika radiační onkologie, Masarykův onkologický ústav, Brno ³; Neurochirurgická klinika, FN u sv. Anny v Brně ⁴
Published in the journal: Klin Onkol 2010; 23(6): 381-387
Category: Přehledy

Summary

Glioblastoma multiforme is one of the most aggressive malignant brain tumours with limited therapeutics options. Standard therapy is maximal surgical resection and adjuvant concurrent chemo‑ radiotherapy and maintenance therapy with temozolomide. This approach improves median and 5‑year survival in comparison with postsurgical radiotherapy alone. Additional predictive and prognostic biomarkers are necessary, especially due to the development of targeted therapy – antibodies and tyrosine kinase inhibitors. These new therapeutic approaches are under intensive investigation. The most promising data currently available are for anti‑angiogenic therapies, such as bevacizumab and cediranib. This review presents a summary of the possible role of targeted therapy in the treatment of glioblastoma multiforme.

Key words:
glioblastoma multiforme – targeted therapy – biomarkers – angiogenesis – VEGF – EGFR – integrins

Zdroje

1. Curran WJ Jr, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85(9): 704– 710.

2. NCCN Clinical Practice Guidelines in Oncology v. 1.2010. Dostupné z http:/ / www.nccn.org/ index.asp.

3. Laws ER, Parney IF, Huang W et al. Glioma Outcomes Investigators. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J Neurosurg 2003; 99(3): 467– 473.

4. Hentschel SJ, Sawaya R. Optimizing outcomes with maximal surgical resection of malignant gliomas. Cancer Control 2003; 10(2): 190– 214.

5. Amelio D, Lorentini S, Schwarz M et al. Intensity‑ modulated radiation therapy in newly diagnosed glioblastoma: A systematic review on clinical and technical issues. Radiother Oncol 2010; 97(3): 361– 369.

6. Stupp R, Mason WP, van den Bent MJ et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352(10): 987– 996.

7. Stupp R, Hegi ME, Mason WP et al. European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5‑year analysis of the EORTC‑ NCIC trial. Lancet Oncol 2009; 10(5): 459– 466.

8. Brandes AA, Vastola F, Basso U et al. A prospective study on glioblastoma in elderly. Cancer 2003; 97(3): 657– 662.

9. Nečesalová E, Kuglík P, Cejpek P et al. Studium polyzomie chromozomu 7, monozomie chromozomu 10, amplifikace genu EGFR a delece genu p53 u multiformního glioblastomu pomocí metody fluorescenční in situ hybridizace (FISH). Klin Onkol 2006; 19(1): 9– 14.

10. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285(21): 1182– 1186.

11. Jain RK. Normalizing tumor vasculature with anti‑angiogenic therapy : a new paradigm for combination therapy. Nat Med 2001; 7(9): 987– 989.

12. Glass J, Gruber LM, Nirenberg A. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high‑grade gliomas. ASCO Proceedings. J Clin Oncol 1999; 18 (Suppl): 144.

13. Pope WB, Lai A, Nghiemphu P et al. MRI in patients with high‑grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006; 66: 1258– 1260.

14. Chen W, Delaloye S, Silverman DH et al. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: A pilot study. J Clin Oncol 2007; 25: 4714– 4721.

15. Vredenburgh JJ, Desjardins A, Herndon JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25(30): 4722– 4729.

16. Friedman HS, Prados MD, Wen PY et al. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. J Clin Oncol 2009; 27(28): 4733– 4740.

17. Narayana A, Golfinos JG, Fisher I et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high‑grade glioma. Int J Radiat Oncol Biol Phys 2008; 72: 383– 389.

18. Radiation Therapy Oncology Group 0825, American College of Radiology. Phase III double‑blind placebo‑ controlled trial of conventional concurrent chemoradiation and adjuvant temozolomide plus bevacizumab versus conventional concurrent chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma [online]. September 29, 2009. Cited 2010– 01– 20. Dostupné z http:/ / www.rtog.org/ members/ protocols/ 0825/ 0825.pdf.

19. De Groot JF, Wen PY, Lamborn K et al. Phase II single arm trial of aflibercept in patients with recurrent temozolomide‑resistant glioblastoma: NABTC 0601. American Society of Clinical Oncology 44th Annual Meeting, Chicago, IL, USA. May‑ June 2008. Abstract 2020.

20. Batchelor TT, Duda DG, di Tomaso E et al. Phase II study of cediranib, an oral pan‑ vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28(17): 2817– 2823.

21. Neyns B, Sadones J, Joosens E et al. Stratified phase II trial of cetuximab in patients with recurrent high‑grade glioma. Ann Oncol 2009; 20(9): 1596– 1603.

22. Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22(1): 133– 142.

23. Peereboom DM, Shepard DR, Ahluwalia MS et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 2010; 98(1): 93– 99.

24. Chakravarti A, Seiferheld W, Tu X et al. Immunohistochemically determined total epidermal growth factor receptor levels not of prognostic value in newly diagnosed glioblastoma multiforme: report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62(2): 318– 327.

25. Wen PY, Yung WK, Lamborn KR et al. Phase I/ II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99– 08. Clin Cancer Res 2006; 12(16): 4899– 4907.

26. Van den Bent M, Brandes A, Frenay M et al. Multicentre phase II study of imatinib mesylate (Glivec®) in patients with recurrent anaplastic oligodendroglioma (AOD)/ mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/ low grade astrocytoma (LGA): an EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study. ASCO Meeting Abstract, J Clin Oncol 2005; 23 (Suppl): 1517.

27. Galanis E, Buckner JC, Maurer MJ et al. North Central Cancer Treatment Group. Phase II trial of temsirolimus (CCI‑ 779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005; 23(23): 5294– 5304.

28. Nabors LB, Mikkelsen T, Rosenfeld SS et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007; 25(13): 1651– 1657.

29. Reardon DA, Fink KL, Mikkelsen T et al. Randomized phase II study of cilengitide: An integrin‑targeting arginine‑ glycine‑ aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 2008; 26(34): 5610– 5617.

30. Chamberlain M. Cilengitide: Does it really represent a new targeted therapy for recurrent glioblastoma? J Clin Oncol 2009; 27(11): 1921.

31. Fine HA, Kim L, Royce C et al. Results from phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas. 2005 ASCO Annual Meeting Proceedings. J Clin Oncol 2005; 23 (Suppl 16): 1504.

32. Wick W, Puduvalli VK, Chamberlain MC et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 2010; 28(7): 1168– 1174.